CI

At a glance

ClinicalIndex Comparison Record
Phase 4Active· 260 enrolled
Drug / intervention
Dexamethasone +1 moredrug
Likely dose
Dexamethasone 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04025840
NCT04025840Phase 4Active

Effect of Perioperative Epidural Block and Dexamethasone on Outcome of Patients Undergoing Pancreatic Cancer Surgery: a 2×2 Factorial Randomized Controlled Trial

Peking University First Hospital·interventional·Posted Jul 19, 2019·Updated Jul 31, 2025

In Brief

A Phase 4 clinical trial evaluating Epidural block and Dexamethasone for Pancreatic Cancer and 4 related conditions. Active but no longer recruiting, targeting 260 participants across 1 site.

Detailed Summary

Pancreatic cancer remains a devastating disease with an average 5-year survival rate of about 3-5%. Previous retrospective studies showed that perioperative epidural block and/or dexamethasone are associated with improved outcome after cancer surgery. This randomized trial aims to investigate the effect of perioperative epidural block and/or dexamethasone on long-term survival in patients following pancreatic cancer surgery.

Study Details

Timeline

Phase 4Active
20202021202220232024202520262027
First PostedJul 19, 2019
Enrollment StartSep 11, 2019
Primary CompletionOct 22, 2024
Study CompletionNov 1, 2026
TodayJul 1, 2026
Enrollment to primary: 5.1 yearsPosted 7.0 years ago

Interventions

Epidural blockother

Epidural block (with 0.375% ropivacaine) is performed during surgery. Patient-controlled epidural analgesia (with a mixture of 0.12% ropivacaine and 0.5 microgram/ml sufentanyl) is provided after surgery.

Dexamethasonedrug

Dexamethasone (10 mg) is administered intravenously before anesthesia induction.